Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Journal of Clinical Hepatology ; (12): 2575-2579, 2023.
Artigo em Chinês | WPRIM | ID: wpr-998812

RESUMO

ObjectiveTo investigate the situation and development trend of the disease burden of acute hepatitis B in China in 1990 — 2019. MethodsThe Global Burden of Disease 2019 was used to analyze the incidence rate, mortality rate, and disability-adjusted life year (DALY) rate of acute hepatitis B in different sex and age groups and predict the trend of the incidence rate of acute hepatitis B. ResultsIn 2019, the incidence rate, mortality rate, and DALY rate of acute hepatitis B in China were 1 623.71/100 000, 0.20/100 000, and 10.04/100 000 respectively, which were reduced by 42.03%, 79.38%, and 80.21%, respectively, compared with the data in 1990, and women showed lower incidence rate, mortality rate, and DALY rate of acute hepatitis B than men. In 2019, the 20~<54 years group had the highest incidence rate (2 285.85/100 000) and DALY rate (10.53/100 000), and the ≥55 years group had the highest mortality rate of 0.52/100 000. The Joinpoint regression model analysis showed that the incidence rate, mortality rate, and DALY rate of acute hepatitis B in China tended to decrease from 1990 to 2019, with an average annual percent change of -1.9%, -5.2%, and -5.5%, respectively (P<0.05). The grey prediction model GM (1,1) showed that the incidence rate of acute hepatitis B will decrease from 2020 to 2030 in China. ConclusionThe disease burden of acute hepatitis B tended to decrease from 1990 to 2019 in China, indicating that the prevention and treatment measures for acute hepatitis B have achieved a marked effect in China; however, due to the large population base of China, active preventive measures should be further adopted to reduce the disease burden of acute hepatitis B.

2.
Journal of Leukemia & Lymphoma ; (12): 635-638, 2015.
Artigo em Chinês | WPRIM | ID: wpr-477393

RESUMO

Lymphoma is one of the diseases that could be cured through chemoradiotherapy, so the early efficacy evaluation can help us to realize the optimal treatment and individualized treatment.CT perfusion is a functional imaging technology which can indirectly reflect the changes in tissue in physiologica and metabolic, and provide the reliable biomarkers for early efficacy evaluation of tumors.This paper focuses on the relevant research of CT perfusion imaging in the early efficacy evaluation of lymphoma at home and abroad in recent years.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA